TY - JOUR
T1 - Biomarkers in Search of Precision Medicine in IBD
AU - Boyapati, Ray K.
AU - Kalla, Rahul
AU - Satsangi, Jack
AU - Ho, Gwo Tzer
PY - 2016/12/1
Y1 - 2016/12/1
N2 - The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As "big data", driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of "precision medicine" - precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
AB - The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As "big data", driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of "precision medicine" - precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
UR - http://www.scopus.com/inward/record.url?scp=84988720232&partnerID=8YFLogxK
U2 - 10.1038/ajg.2016.441
DO - 10.1038/ajg.2016.441
M3 - Review Article
C2 - 27670602
AN - SCOPUS:84988720232
SN - 0002-9270
VL - 111
SP - 1682
EP - 1690
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 12
ER -